 CORAL GABLES, Fla., March 16, 2022 PRNewswire -- Relmada Therapeutics, Inc. Nasdaq: RLMD, a late-stage biotechnology company addressing diseases of the central nervous system CNS, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021 after the market close on Wednesday, March 23, 2022. 